secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001070081-25-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics Q3 net income $15.9M, Sephience launch revenue $19.6M
----------------------------------------------------------------------

- Total revenue $211.0M vs $196.8M YoY; net income $15.9M vs loss of $106.7M.
- Sephience launch: $19.6M revenue (US $14.4M, ex-US $5.2M), 521 start forms from 141 prescribers, 341 patients on therapy.
- DMD franchise revenue $85.9M (Translarna $50.7M, Emflaza $35.2M); Evrysdi royalties $70.8M.
- Full-year 2025 revenue guidance narrowed to $750-$800M; GAAP R&D/SG&A $805-$835M.
- Cash and marketable securities $1,687.8M as of Sep 30, 2025 (up from $1,139.7M at Dec 31, 2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008125000026/0001070081-25-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008125000026/tmb-20251104x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-25-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer